JP2022185052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022185052A5 JP2022185052A5 JP2022156496A JP2022156496A JP2022185052A5 JP 2022185052 A5 JP2022185052 A5 JP 2022185052A5 JP 2022156496 A JP2022156496 A JP 2022156496A JP 2022156496 A JP2022156496 A JP 2022156496A JP 2022185052 A5 JP2022185052 A5 JP 2022185052A5
- Authority
- JP
- Japan
- Prior art keywords
- rna molecule
- vector
- synthetic rna
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002477 rna polymer Polymers 0.000 claims 27
- 239000013598 vector Substances 0.000 claims 13
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 5
- 239000004055 small Interfering RNA Substances 0.000 claims 5
- 239000013603 viral vector Substances 0.000 claims 5
- 101150079354 rho gene Proteins 0.000 claims 4
- 108700011259 MicroRNAs Proteins 0.000 claims 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 230000003252 repetitive effect Effects 0.000 claims 3
- 108091081021 Sense strand Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 108091026821 Artificial microRNA Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000013613 expression plasmid Substances 0.000 claims 1
- 230000030279 gene silencing Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024168632A JP2025016451A (ja) | 2016-03-01 | 2024-09-27 | 優性網膜色素変性の治療のためのａａｖベクター |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302122P | 2016-03-01 | 2016-03-01 | |
| US62/302,122 | 2016-03-01 | ||
| US201662398451P | 2016-09-22 | 2016-09-22 | |
| US62/398,451 | 2016-09-22 | ||
| PCT/US2017/020289 WO2017151823A1 (en) | 2016-03-01 | 2017-03-01 | Aav vectors for treatment of dominant retinitis pigmentosa |
| JP2018545818A JP7272795B2 (ja) | 2016-03-01 | 2017-03-01 | 優性網膜色素変性の治療のためのａａｖベクター |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545818A Division JP7272795B2 (ja) | 2016-03-01 | 2017-03-01 | 優性網膜色素変性の治療のためのａａｖベクター |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168632A Division JP2025016451A (ja) | 2016-03-01 | 2024-09-27 | 優性網膜色素変性の治療のためのａａｖベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022185052A JP2022185052A (ja) | 2022-12-13 |
| JP2022185052A5 true JP2022185052A5 (https=) | 2023-05-01 |
| JP7642211B2 JP7642211B2 (ja) | 2025-03-10 |
Family
ID=59743213
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545818A Active JP7272795B2 (ja) | 2016-03-01 | 2017-03-01 | 優性網膜色素変性の治療のためのａａｖベクター |
| JP2022156496A Active JP7642211B2 (ja) | 2016-03-01 | 2022-09-29 | 優性網膜色素変性の治療のためのａａｖベクター |
| JP2024168632A Pending JP2025016451A (ja) | 2016-03-01 | 2024-09-27 | 優性網膜色素変性の治療のためのａａｖベクター |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545818A Active JP7272795B2 (ja) | 2016-03-01 | 2017-03-01 | 優性網膜色素変性の治療のためのａａｖベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168632A Pending JP2025016451A (ja) | 2016-03-01 | 2024-09-27 | 優性網膜色素変性の治療のためのａａｖベクター |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11118185B2 (https=) |
| EP (2) | EP3423582B1 (https=) |
| JP (3) | JP7272795B2 (https=) |
| CN (2) | CN115896106A (https=) |
| AU (2) | AU2017227776C1 (https=) |
| CA (1) | CA3014671A1 (https=) |
| ES (1) | ES2923877T3 (https=) |
| IL (2) | IL302455A (https=) |
| WO (1) | WO2017151823A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115896106A (zh) | 2016-03-01 | 2023-04-04 | 佛罗里达大学研究基金会有限公司 | 用于治疗显性视网膜色素变性的aav载体 |
| JP7385282B2 (ja) * | 2017-11-07 | 2023-11-22 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 環状ｒｎａ分子のための方法及び組成物 |
| BR112020023298A2 (pt) * | 2018-05-15 | 2021-03-09 | University Of Washington | composições e métodos para reduzir a spliceopatia e tratamento de distúrbios de dominância de rna |
| CN112204145B (zh) * | 2018-06-01 | 2024-03-26 | 佛罗里达大学研究基金会有限公司 | 用于治疗显性视网膜色素变性的组合物和方法 |
| GB201817469D0 (en) * | 2018-10-26 | 2018-12-12 | Univ Oxford Innovation Ltd | Gene therapy for retinal disease |
| CN111518813B (zh) * | 2019-02-03 | 2023-04-28 | 武汉纽福斯生物科技有限公司 | 视紫红质的编码序列、其表达载体构建及其应用 |
| EP4013414A4 (en) * | 2019-08-15 | 2023-09-27 | The Children's Hospital of Philadelphia | COMBINED INTRON-DERIVED MIRNA AND TRANSGENE THERAPY FOR THE TREATMENT OF SCA1 |
| US20230149439A1 (en) * | 2020-04-21 | 2023-05-18 | Chigenovo Co., Ltd. | Rho-adrp gene editing-based methods and compositions |
| CN111926044B (zh) * | 2020-10-12 | 2021-01-22 | 北京大学第三医院（北京大学第三临床医学院） | 结合突变rho基因的核酸分子和试剂盒 |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| WO2025231487A1 (en) * | 2024-05-03 | 2025-11-06 | The Trustees Of The University Of Pennsylvania | Photoreceptor specific promotors for use in gene therapies for treatment of retinal degeneration |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US8551970B2 (en) | 1996-04-02 | 2013-10-08 | Optigen Patents Limited | Genetic suppression and replacement |
| US20040234999A1 (en) | 1996-04-02 | 2004-11-25 | Farrar Gwenyth Jane | Genetic suppression and replacement |
| GB9606961D0 (en) | 1996-04-02 | 1996-06-05 | Farrar Gwyneth J | Genetic strategy III |
| AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
| AU2004233043A1 (en) | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2 |
| US20070009899A1 (en) * | 2003-10-02 | 2007-01-11 | Mounts William M | Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases |
| GB0403600D0 (en) * | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
| CN1977044A (zh) | 2004-03-24 | 2007-06-06 | 肿瘤疗法科学股份有限公司 | 治疗胰腺癌的组合物和方法 |
| US20080221057A1 (en) | 2007-02-16 | 2008-09-11 | Wyeth | Secreted protein ccdc80 regulates adipocyte differentiation |
| US20120322861A1 (en) | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
| EP2140004B1 (en) * | 2007-04-12 | 2022-01-12 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Genetic suppression and replacement |
| WO2009035792A1 (en) * | 2007-08-03 | 2009-03-19 | Melba Ketchum | Compositions, methods and systems for the simultaneous determination of parentage, identity, sex, genotype and/or phenotype and breed determination in animals |
| WO2010127209A2 (en) * | 2009-04-30 | 2010-11-04 | The Research Foundation Of State University Of New York | Compositions and methods for therapy of macular degeneration |
| SG10201800541SA (en) * | 2010-04-23 | 2018-03-28 | Univ Florida | Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1) |
| KR101761388B1 (ko) | 2010-07-30 | 2017-07-25 | 큐어백 아게 | 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체 |
| CN102061308B (zh) | 2010-10-29 | 2013-05-08 | 北京未名凯拓作物设计中心有限公司 | 一种用百草枯筛选转基因植物的方法 |
| CN102061305B (zh) | 2010-12-15 | 2012-07-18 | 深圳市百恩维生物科技有限公司 | 一种多ShRNA高效协同沉默基因方法及载体 |
| US20130064815A1 (en) | 2011-09-12 | 2013-03-14 | The Trustees Of Princeton University | Inducing apoptosis in quiescent cells |
| US11180760B2 (en) * | 2012-03-09 | 2021-11-23 | The Johns Hopkins University | Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders |
| US9163259B2 (en) * | 2012-05-04 | 2015-10-20 | Novartis Ag | Viral vectors for the treatment of retinal dystrophy |
| US9695443B2 (en) | 2012-05-25 | 2017-07-04 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Vector for the selective silencing of a gene in astrocytes |
| WO2014138792A1 (en) | 2013-03-14 | 2014-09-18 | Commonwealth Scientific And Industrial Research Organisation | Double-stranded rna |
| PL3628334T3 (pl) * | 2014-03-21 | 2023-12-18 | Genzyme Corporation | Terapia genowa w retinopatii barwnikowej |
| AU2016222546B2 (en) | 2015-02-26 | 2020-01-23 | Ionis Pharmaceuticals, Inc. | Allele specific modulators of P23H rhodopsin |
| EP3289080B1 (en) | 2015-04-30 | 2021-08-25 | The Trustees of Columbia University in the City of New York | Gene therapy for autosomal dominant diseases |
| WO2017137493A1 (en) | 2016-02-09 | 2017-08-17 | Fondazione Telethon | Synthetic promoters and uses thereof |
| US20170348387A1 (en) | 2016-02-29 | 2017-12-07 | The Trustees Of The University Of Pennsylvania | Aav-mediated gene therapy for nphp5 lca-ciliopathy |
| CN115896106A (zh) | 2016-03-01 | 2023-04-04 | 佛罗里达大学研究基金会有限公司 | 用于治疗显性视网膜色素变性的aav载体 |
-
2017
- 2017-03-01 CN CN202210934990.0A patent/CN115896106A/zh active Pending
- 2017-03-01 IL IL302455A patent/IL302455A/en unknown
- 2017-03-01 EP EP17760752.0A patent/EP3423582B1/en active Active
- 2017-03-01 IL IL261014A patent/IL261014B2/en unknown
- 2017-03-01 EP EP22170988.4A patent/EP4119668A1/en active Pending
- 2017-03-01 CN CN201780014309.8A patent/CN109154002B/zh active Active
- 2017-03-01 WO PCT/US2017/020289 patent/WO2017151823A1/en not_active Ceased
- 2017-03-01 CA CA3014671A patent/CA3014671A1/en active Pending
- 2017-03-01 AU AU2017227776A patent/AU2017227776C1/en active Active
- 2017-03-01 JP JP2018545818A patent/JP7272795B2/ja active Active
- 2017-03-01 ES ES17760752T patent/ES2923877T3/es active Active
- 2017-03-01 US US16/081,307 patent/US11118185B2/en active Active
-
2021
- 2021-05-21 US US17/327,609 patent/US20210324387A1/en active Pending
-
2022
- 2022-09-29 JP JP2022156496A patent/JP7642211B2/ja active Active
-
2023
- 2023-09-27 AU AU2023237106A patent/AU2023237106B2/en active Active
-
2024
- 2024-09-27 JP JP2024168632A patent/JP2025016451A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022185052A5 (https=) | ||
| JP2025016451A5 (https=) | ||
| EP2633051B1 (en) | Hbv treatment | |
| US9150863B2 (en) | Compositions and methods for siRNA inhibition of angiogenesis | |
| JP2019511216A5 (https=) | ||
| US8470792B2 (en) | Compositions and methods for selective inhibition of VEGF | |
| US7872118B2 (en) | siRNA and methods of manufacture | |
| JP2011505833A5 (https=) | ||
| US8227444B2 (en) | Compositions and methods for inhibition of VEGF | |
| JP2009535039A5 (https=) | ||
| JP2024119830A5 (https=) | ||
| JP2021525531A5 (https=) | ||
| JP2020503014A5 (https=) | ||
| JP2021534796A5 (https=) | ||
| JP2019513395A5 (https=) | ||
| KR101286053B1 (ko) | ＴＧＦ－β１ 발현을 억제하는 ｓｈＲＮＡ | |
| US9790502B2 (en) | HBV treatment | |
| JP2005253342A (ja) | ヒトチミジル酸合成酵素に対するＲＮＡｉとして作用するＲＮＡ配列 | |
| JP2018513841A5 (https=) | ||
| WO2012109798A1 (en) | Hbv treatment | |
| HK1234090B (en) | Hbv treatment |